

放疗联合阿替利珠单抗和贝伐珠单抗治疗肝癌合并门静脉癌栓的有效性和安全性：开放、单臂探索性研究

下载XML文档

注册号: Registration number:	ChiCTR2100049831
最近更新日期: Date of Last Refreshed on:	2022-04-15
注册时间: Date of Registration:	2021-08-10
注册号状态:	预注册
Registration Status:	Prospective registration
注册题目:	放疗联合阿替利珠单抗和贝伐珠单抗治疗肝癌合并门静脉癌栓的有效性和安全性：开放、单臂探索性研究
Public title:	Efficacy and safety of radiotherapy combined with Atezolizumab plus Bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus: an open-label, single-arm, exploratory trial
注册题目简写:	
English Acronym:	
研究课题的正式科学名称:	放疗联合阿替利珠单抗和贝伐珠单抗治疗肝癌合并门静脉癌栓的有效性和安全性：开放、单臂探索性研究
Scientific title:	Efficacy and safety of radiotherapy combined with Atezolizumab plus Bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus: an open-label, single-arm, exploratory trial
研究课题代号(代码): Study subject ID:	
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register:	
申请注册联系人: 王康	研究负责人: 王康
Applicant: Wang Kang	Study leader: Wang Kang
申请注册联系人电话: Applicant telephone:	研究负责人电话: Study leader's telephone:
+86 18817302388	+86 18817302388
申请注册联系人传真: Applicant Fax:	研究负责人传真: Study leader's fax:
申请注册联系人电子邮件: Applicant E-mail:	研究负责人电子邮件: Study leader's E-mail:
wangkang_md@aliyun.com	wangkang_md@aliyun.com
申请单位网址(自愿提供): Applicant website(voluntary supply):	研究负责人网址(自愿提供): Study leader's website(voluntary supply):